AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12362968 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT + aftercare
Number of subjects: 90
Study 12362968 — intervention group
Group type: COMPARATOR
Intervention: Al‐Nar FT
Number of subjects: 90
Study 10435146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Balance gel and Biotene toothpaste
Number of subjects: 0
Study 10435146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carboxymethylcellulose gel and commercial toothpaste)
Number of subjects: 0
Study 7852526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg.day gallium nitrate
Number of subjects: 49
Study 7852526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg.day gallium nitrate
Number of subjects: 49
Study 7852526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg.day gallium nitrate
Number of subjects: 49
Study 7852526 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 49
Study 2087618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifluril (400 mg daily, morniflumate)
Number of subjects: 79
Study 2087618 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicilline (50 mg/kg daily)
Number of subjects: 79
Study 2087618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 358728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol alone
Number of subjects: 92
Study 358728 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2alpha alone
Number of subjects: 92
Study 358728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol combined with PGF2alpha
Number of subjects: 92
Study 358728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol combined with half dose PGF2alpha
Number of subjects: 92
Study 358728 — intervention group
Group type: COMPARATOR
Intervention: Rivanol
Number of subjects: 92
Study 358728 — intervention group
Group type: COMPARATOR
Intervention: PGF2alpha
Number of subjects: 92
Study 29557414 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic 'Symbiter' (14 probiotic bacteria genera)
Number of subjects: 58
Study 29557414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 29557414 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic 'Symbiter'
Number of subjects: 58
Study 26489835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) twice daily for 2 weeks at 30% of maximal inspiratory pressure, in addition to standard postoperative physiotherapy.
Number of subjects: 68
Study 26489835 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (breathing exercises, coughing techniques, early mobilization)
Number of subjects: 68
Study 26489835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 68
Study 24944159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/d
Number of subjects: 502
Study 24944159 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/d
Number of subjects: 502
Study 22339611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 22339611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0
Study 22339611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and SSRIs
Number of subjects: 0
Study 20730073 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 53
Study 20730073 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 53
Study 20730073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Candesartan and CCBs)
Number of subjects: 53
Study 17089413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 93
Study 17089413 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 93
Study 17089413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 15192693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure phosphene tonometry using Proview eye pressure monitor
Number of subjects: 100
Study 15192693 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometry
Number of subjects: 100
Study 11892706 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID for 6 weeks (OA)
Number of subjects: 1711
Study 11892706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg BID or TID for 6 weeks (OA)
Number of subjects: 1711
Study 11892706 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks (OA)
Number of subjects: 1711
Study 11892706 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID for 24 weeks (RA)
Number of subjects: 1711
Study 11892706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg BID for 24 weeks (RA)
Number of subjects: 1711
Study 11892706 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (both OA and RA)
Number of subjects: 1711
Study 10333347 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 10 mg
Number of subjects: 122
Study 10333347 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 40 mg
Number of subjects: 122
Study 10333347 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg
Number of subjects: 122
Study 10333347 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Number of subjects: 122
Study 10333347 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 122
Study 7795831 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss alone
Number of subjects: 2382
Study 7795831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction alone
Number of subjects: 2382
Study 7795831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of weight loss and sodium reduction
Number of subjects: 2382
Study 7795831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2382
Study 1799913 — intervention group
Group type: EXPERIMENTAL
Intervention: rDNA HI (BY)
Number of subjects: 65
Study 1799913 — intervention group
Group type: COMPARATOR
Intervention: ssHI
Number of subjects: 65
Study 6992260 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy without drainage (HSV)
Number of subjects: 0
Study 6992260 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty (SV)
Number of subjects: 0
Study 31775668 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized psychotherapy starting prenatal and lasting for 10 months
Number of subjects: 100
Study 31775668 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention following psychotherapy
Number of subjects: 100
Study 31775668 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy women
Number of subjects: 100
Study 28525534 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of docetaxel followed by three cycles of fluorouracil, epirubicin and cyclophosphamide once every 21 days with four cycles of bevacizumab
Number of subjects: 800
Study 28525534 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of docetaxel followed by three cycles of fluorouracil, epirubicin and cyclophosphamide once every 21 days without bevacizumab
Number of subjects: 800
Study 25915145 — intervention group
Group type: EXPERIMENTAL
Intervention: Precut Kinesiology Tape (PCT) and Exercise (n = 33)
Number of subjects: 100
Study 25915145 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID and Exercise (n = 29)
Number of subjects: 100
Study 25915145 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (n = 38)
Number of subjects: 100
Study 24477242 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 12
Study 24477242 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 22108775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg once daily
Number of subjects: 24
Study 22108775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 24
Study 19614621 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib (3, 4.5, and 6 mg/kg/day)
Number of subjects: 44
Study 19614621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19614621 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 44
Study 17968637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan medicine
Number of subjects: 0
Study 17968637 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 0
Study 15311147 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg)
Number of subjects: 877
Study 15311147 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg) after missed dose
Number of subjects: 877
Study 15311147 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80-160 mg)
Number of subjects: 877
Study 15311147 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80-160 mg) after missed dose
Number of subjects: 877
Study 12074234 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement loaded with 3% sodium fluoride
Number of subjects: 75
Study 12074234 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement loaded with 2% sodium fluoride
Number of subjects: 75
Study 12074234 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement loaded with 1% sodium fluoride
Number of subjects: 75
Study 12074234 — intervention group
Group type: COMPARATOR
Intervention: Non-loaded resin-modified glass-ionomer cement
Number of subjects: 75
Study 12074234 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated resin-based composite
Number of subjects: 75
Study 9501889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline during the luteal phase
Number of subjects: 31
Study 9501889 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the luteal phase
Number of subjects: 31
Study 8478238 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 fractions of 2.5 Gy per week
Number of subjects: 32
Study 8478238 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 fractions of 2 Gy per week
Number of subjects: 32
Study 8478238 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 3093915 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 45
Study 3093915 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition (NG)
Number of subjects: 45
Study 31645364 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a web-based decision support tool for antidepressant treatment
Number of subjects: 0
Study 31645364 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 29709378 — intervention group
Group type: EXPERIMENTAL
Intervention: Redistributed inhomogeneous boosting to the GTV subvolume (FDG-SUV > 50% SUVmax)
Number of subjects: 82
Study 29709378 — intervention group
Group type: COMPARATOR
Intervention: Homogeneous boosting to the primary tumor
Number of subjects: 82
Study 29709378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 82
Study 26842902 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for CrCl ≥ 50 ml/min or 7.5 mg once daily for CrCl ≥ 30 ml/min and < 50 ml/min for 45 days
Number of subjects: 8000
Study 26842902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study 24576226 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified menotropin (HP-hMG)
Number of subjects: 343
Study 24576226 — intervention group
Group type: COMPARATOR
Intervention: Recombinant follicle-stimulating hormone (rFSH)
Number of subjects: 343
Study 23302475 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM (self‐directed Internet‐delivered cognitive‐behavioral skills training tool)
Number of subjects: 3070
Study 23302475 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting-list control)
Number of subjects: 3070
Study 20206060 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation
Number of subjects: 0
Study 20206060 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional exercise training)
Number of subjects: 0
Study 17399674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clariflex IOL with OptiEdge (sharp posterior optic edge)
Number of subjects: 52
Study 17399674 — intervention group
Group type: COMPARATOR
Intervention: SI40 IOL (round edges)
Number of subjects: 52
Study 15769490 — intervention group
Group type: COMPARATOR
Intervention: Children with ASD
Number of subjects: 0
Study 15769490 — intervention group
Group type: EXPERIMENTAL
Intervention: Typically developing children
Number of subjects: 0
Study 11939913 — intervention group
Group type: EXPERIMENTAL
Intervention: A-line Arx Index (AAI)
Number of subjects: 24
Study 11939913 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Evoked Potentials (AEP)
Number of subjects: 24
Study 11939913 — intervention group
Group type: COMPARATOR
Intervention: Modified Observers Assessment of Alertness and Sedation Scale (MOAAS)
Number of subjects: 24
Study 9499185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C, epirubicin and cisplatin (MEP)
Number of subjects: 84
Study 9499185 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C alone (MITOC)
Number of subjects: 84
Study 7747227 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Number of subjects: 80
Study 7747227 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Number of subjects: 80
Study 7747227 — intervention group
Group type: COMPARATOR
Intervention: Myelography
Number of subjects: 80
Study 2144819 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (FLU)
Number of subjects: 100
Study 2144819 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA)
Number of subjects: 100
Study 6118522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine alone
Number of subjects: 59
Study 6118522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine + Fansidar
Number of subjects: 59
Study 6118522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine + Tetracycline (for 10 days)
Number of subjects: 59
Study 31575059 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose POP (8.7 mg/d)
Number of subjects: 60
Study 31575059 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose POP (15.2 mg/d)
Number of subjects: 60
Study 31575059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose POP (37.2 mg/d)
Number of subjects: 60
Study 31575059 — intervention group
Group type: COMPARATOR
Intervention: Control (no added PS or POP)
Number of subjects: 60
Study 28898281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 61
Study 28898281 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 61
Study 25805647 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month intervention (physician/pharmacist collaborative model)
Number of subjects: 625
Study 25805647 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 and 24-month intervention (physician/pharmacist collaborative model)
Number of subjects: 625
Study 25805647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 625
Study 23662986 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone phosphate
Number of subjects: 89
Study 23662986 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 89
Study 23662986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 21297322 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnett's test for psychogenic abdominal pain
Number of subjects: 130
Study 21297322 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnett's test for abdominal wall pain
Number of subjects: 130
Study 21297322 — intervention group
Group type: COMPARATOR
Intervention: Carnett's test for intra-abdominal pain
Number of subjects: 130
Study 19483236 — intervention group
Group type: EXPERIMENTAL
Intervention: Translocation of the proximal nerve stump into an adjacent subcutaneous vein
Number of subjects: 20
Study 19483236 — intervention group
Group type: COMPARATOR
Intervention: Resection of the neuroma and translocation into muscle tissue
Number of subjects: 20
Study 17130139 — intervention group
Group type: EXPERIMENTAL
Intervention: More extensive brief intervention (BI)
Number of subjects: 4008
Study 17130139 — intervention group
Group type: COMPARATOR
Intervention: Minimal brief intervention (BI)
Number of subjects: 4008
Study 17130139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BI types
Number of subjects: 4008
Study 15562051 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective spinal anesthesia (SSA) with 4 mg of hyperbaric bupivacaine
Number of subjects: 64
Study 15562051 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with desflurane
Number of subjects: 64
Study 11305522 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) Doppler
Number of subjects: 20
Study 11305522 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution technique
Number of subjects: 20
Study 11305522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9643792 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing at 15 breaths per min
Number of subjects: 50
Study 9643792 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing at 6 breaths per min
Number of subjects: 50
Study 9643792 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing at 3 breaths per min
Number of subjects: 50
Study 9643792 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of respiratory training to decrease breathing rate to 6 breaths per min
Number of subjects: 50
Study 9643792 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (baseline)
Number of subjects: 50
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole and G-CSF administered simultaneously (Group I)
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole administered later during G-CSF administration (Group II)
Number of subjects: 105
Study 7542301 — intervention group
Group type: COMPARATOR
Intervention: Only miconazole administered (Group III)
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts increased from <500/microliters to >500/microliters (Group I)
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts increased from <500/microliters to >500/microliters (Group II)
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts <500/microliters throughout miconazole administration (Group I)
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts <500/microliters throughout miconazole administration (Group II)
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects in Group I
Number of subjects: 105
Study 7542301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects in Group II
Number of subjects: 105
Study 7542301 — intervention group
Group type: COMPARATOR
Intervention: Adverse effects in Group III
Number of subjects: 105
Study 2572323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 32
Study 2572323 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 32
Study 2008 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylazosulfapyridine, prednisone, and 6-mercaptopurine (alone and in combinations)
Number of subjects: 0
Study 2008 — intervention group
Group type: COMPARATOR
Intervention: Control group (noncolitis controls)
Number of subjects: 0
Study 30507702 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 0
Study 30507702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone in prepubertal boys
Number of subjects: 0
Study 30507702 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 0
Study 28170282 — intervention group
Group type: EXPERIMENTAL
Intervention: UD‐DPI (1.6% blend)
Number of subjects: 0
Study 28170282 — intervention group
Group type: COMPARATOR
Intervention: Diskus (600 μg dose)
Number of subjects: 0
Study 28170282 — intervention group
Group type: COMPARATOR
Intervention: MDI (600 μg dose)
Number of subjects: 0
Study 28170282 — intervention group
Group type: COMPARATOR
Intervention: Diskus
Number of subjects: 0
Study 28170282 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 0
Study 26078203 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 3 days per week
Number of subjects: 30
Study 26078203 — intervention group
Group type: COMPARATOR
Intervention: Resistance training 2 days per week
Number of subjects: 30
Study 23839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline calcium 0.6 mg/kg/day
Number of subjects: 100
Study 23839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline calcium 1.2 mg/kg/day
Number of subjects: 100
Study 23839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline calcium 2.4 mg/kg/day
Number of subjects: 100
Study 23839182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21216540 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcilis PCV(®) vaccine, 2 mL intramuscular dose
Number of subjects: 818
Study 21216540 — intervention group
Group type: COMPARATOR
Intervention: Diluvac Forte(®) adjuvant, 2 mL intramuscular dose
Number of subjects: 818
Study 19474425 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 127
Study 19474425 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 127
Study 17548839 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (oral capecitabine 1,000 mg/m2 bid for 14 days plus oxaliplatin 130 mg/m2 on day 1 every 3 weeks)
Number of subjects: 348